Cash, cash equivalents, restricted cash and short-term investments totaled $84.5 million as of March 31, 2025, before accounting for the proceeds pending the close of the PRV sale. As of December 31, 2024, cash, cash equivalents, restricted cash and short-term investments totaled $98.1 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona, Lurie Children’s opens first center for ZEVASKYN gene therapy
- Abeona Therapeutics: Strong Buy Rating Backed by Financial Stability and Strategic Growth Initiatives
- Abeona Therapeutics Sells Priority Review Voucher for $155M
- Abeona Therapeutics enters agreement to sell PRV for $155M
- ABEO Earnings this Week: How Will it Perform?